WallStreetZenWallStreetZen

NASDAQ: ONCT
Oncternal Therapeutics Inc Stock Ownership - Who owns Oncternal Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Oncternal Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Robert James WillsDirector2024-04-083,086$8.96
$27.65kBuy
Robert James WillsDirector2024-03-286,914$8.48
$58.60kBuy
David F. HaleDirector2024-02-23714$9.04
$6.45kBuy
Robert James WillsDirector2024-02-23980$9.04
$8.86kSell
David F. HaleDirector2024-02-23266$9.04
$2.40kBuy
Salim YazjiChief Medical Officer2024-01-0319,742$0.50
$9.79kSell
James B. BreitmeyerChief Executive Officer2024-01-034,485$0.50
$2.22kSell
James B. BreitmeyerChief Executive Officer2024-01-0350,955$0.50
$25.27kSell
Rajesh KrishnanChief Technical Officer2024-01-0311,838$0.50
$5.87kSell
Chase C. LeavittGeneral CounselSecretary2024-01-0311,838$0.50
$5.87kSell

1 of 2

ONCT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ONCT insiders and whales buy or sell their stock.

ONCT Shareholders

What type of owners hold Oncternal Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Joseph R. Hyde Iii807.11%23,887,655$209.38MInsider
Mitchell Shuster Steiner324.93%9,616,728$84.29MInsider
Jack W. Schuler235.30%6,964,028$61.04MInsider
Shanghai Pharmaceutical Usa Inc204.06%6,039,545$52.94MInsider
Peak Foundation Pyramid148.34%4,390,243$38.48MInsider
Vanguard Group Inc96.66%2,860,906$25.08MInstitution
Millennium Management LLC69.46%2,055,904$18.02MInstitution
Shanghai Pharmaceuticals Hk Investment Ltd35.45%1,049,317$9.20MInsider
Marc Steven Hanover35.08%1,038,366$9.10MInsider
Blackrock Inc26.55%785,681$6.89MInstitution

1 of 3

ONCT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ONCT13.07%86.93%Net SellingNet Buying
ITRM1.70%98.30%Net Buying
SER12.90%87.10%
SLGL28.59%0.00%
SNSE11.82%71.99%Net SellingNet Selling
View Top Biotech Stocks

Oncternal Therapeutics Stock Ownership FAQ

Who owns Oncternal Therapeutics?

Oncternal Therapeutics (NASDAQ: ONCT) is owned by 285.39% institutional shareholders, 1,898.18% Oncternal Therapeutics insiders, and 0.00% retail investors. Joseph R. Hyde Iii is the largest individual Oncternal Therapeutics shareholder, owning 23.89M shares representing 807.11% of the company. Joseph R. Hyde Iii's Oncternal Therapeutics shares are currently valued at $204.12M.

If you're new to stock investing, here's how to buy Oncternal Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.